Search

everythinglearnresearchcommunity

for

Search:↓

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

A cancer patient died from a severe skin reaction after taking the drug cetuximab.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

The drug combination was safe and showed promise in treating advanced tumors.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

CTP-543 is generally safe for treating alopecia areata.

Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.

Baricitinib is more effective than methotrexate for severe alopecia areata.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Ritlecitinib was generally well tolerated in children with alopecia areata.

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.

Topical Ruxolitinib may safely treat severe hair loss.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.